Debt-to-equity of Nabriva Therapeutics plc from 30 Sep 2017 to 30 Jun 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Nabriva Therapeutics plc quarterly Debt-to-equity in % history and change rate from 30 Sep 2017 to 30 Jun 2023.
  • Nabriva Therapeutics plc Debt-to-equity for the quarter ending 30 Jun 2023 was 1295%, a 2575% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Nabriva Therapeutics plc Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q2 2023 1295% +1247% +2575% 30 Jun 2023
Q1 2023 169% +125% +287% 31 Mar 2023
Q4 2022 86% +42% +98% 31 Dec 2022
Q3 2022 58% +12% +26% 30 Sep 2022
Q2 2022 48% -1.4% -2.8% 30 Jun 2022
Q1 2022 44% -10% -19% 31 Mar 2022
Q4 2021 43% -22% -34% 31 Dec 2021
Q3 2021 46% -35% -43% 30 Sep 2021
Q2 2021 50% -51% -50% 30 Jun 2021
Q1 2021 54% -61% -53% 31 Mar 2021
Q4 2020 65% -37% -36% 31 Dec 2020
Q3 2020 81% -2.6% -3.1% 30 Sep 2020
Q2 2020 100% +48% +90% 30 Jun 2020
Q1 2020 115% +77% +202% 31 Mar 2020
Q4 2019 102% +77% +309% 31 Dec 2019
Q3 2019 84% +68% +431% 30 Sep 2019
Q2 2019 53% +37% +237% 30 Jun 2019
Q1 2019 38% +20% +106% 31 Mar 2019
Q4 2018 25% +3.5% +16% 31 Dec 2018
Q3 2018 16% -6.8% -30% 30 Sep 2018
Q2 2018 16% 30 Jun 2018
Q1 2018 18% 31 Mar 2018
Q4 2017 21% 31 Dec 2017
Q3 2017 23% 30 Sep 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.